2022
Meta-analysis of molecular imaging of translocator protein in major depression
Eggerstorfer B, Kim JH, Cumming P, Lanzenberger R, Gryglewski G. Meta-analysis of molecular imaging of translocator protein in major depression. Frontiers In Molecular Neuroscience 2022, 15: 981442. PMID: 36226319, PMCID: PMC9549359, DOI: 10.3389/fnmol.2022.981442.Peer-Reviewed Original ResearchBody mass indexMajor depressive disorderMDD patientsMolecular imaging studiesTranslocator proteinImaging studiesTSPO availabilityPositron emission tomography studyMarkers of neuroinflammationSerotonin transporter availabilityEmission tomography studiesSystematic literature searchTime of scanningEffect sizeMolecular neuroimaging studiesMass indexDepressive disorderHealthy controlsMajor depressionTransporter availabilityHealthy subjectsTreatment statusDepression severityTemporal cortexBrain regionsABCB1 variants and sex affect serotonin transporter occupancy in the brain
Silberbauer LR, Rischka L, Vraka C, Hartmann AM, Godbersen GM, Philippe C, Pacher D, Nics L, Klöbl M, Unterholzner J, Stimpfl T, Wadsak W, Hahn A, Hacker M, Rujescu D, Kasper S, Lanzenberger R, Gryglewski G. ABCB1 variants and sex affect serotonin transporter occupancy in the brain. Molecular Psychiatry 2022, 27: 4502-4509. PMID: 36071112, PMCID: PMC7613909, DOI: 10.1038/s41380-022-01733-1.Peer-Reviewed Original ResearchConceptsMinor allele carriersTransporter occupancyAllele carriersABCB1 single nucleotide polymorphismsBasic clinical variablesCitalopram plasma concentrationsYears of ageMajor allele homozygotesCross-over designPET/MRISERT occupancyClinical variablesTreatment promisesClinical algorithmMajor depressionPlasma concentrationsPrecision pharmacotherapyABCB1 variantsHealthy volunteersABCB1 geneAllele homozygotesSame dosageDrug-target engagementTarget engagementSingle nucleotide polymorphisms
2020
Predicting Antidepressant Citalopram Treatment Response via Changes in Brain Functional Connectivity After Acute Intravenous Challenge
Klöbl M, Gryglewski G, Rischka L, Godbersen GM, Unterholzner J, Reed MB, Michenthaler P, Vanicek T, Winkler-Pjrek E, Hahn A, Kasper S, Lanzenberger R. Predicting Antidepressant Citalopram Treatment Response via Changes in Brain Functional Connectivity After Acute Intravenous Challenge. Frontiers In Computational Neuroscience 2020, 14: 554186. PMID: 33123000, PMCID: PMC7573155, DOI: 10.3389/fncom.2020.554186.Peer-Reviewed Original ResearchBeck Depression InventoryFunctional connectivitySymptom improvementMajor depressionDepression InventoryLong-term antidepressant effectsSelective serotonin reuptake inhibitorsHamilton Depression Rating ScaleResting-state functional magnetic resonanceAcute pharmacological challengeSerotonin reuptake inhibitorsWhole-brain functional connectivityCross-over fashionDepression Rating ScaleMajor depressive disorderHigher lifetime prevalenceBrain functional connectivityDefault mode networkHeterogeneity of responseFunctional magnetic resonanceEscitalopram therapyAntidepressant effectsReuptake inhibitorsStandard medicationIntravenous challenge
2019
The effect of electroconvulsive therapy on cerebral monoamine oxidase A expression in treatment-resistant depression investigated using positron emission tomography
Baldinger-Melich P, Gryglewski G, Philippe C, James GM, Vraka C, Silberbauer L, Balber T, Vanicek T, Pichler V, Unterholzner J, Kranz GS, Hahn A, Winkler D, Mitterhauser M, Wadsak W, Hacker M, Kasper S, Frey R, Lanzenberger R. The effect of electroconvulsive therapy on cerebral monoamine oxidase A expression in treatment-resistant depression investigated using positron emission tomography. Brain Stimulation 2019, 12: 714-723. PMID: 30635228, DOI: 10.1016/j.brs.2018.12.976.Peer-Reviewed Original ResearchConceptsElectroconvulsive therapyTRD patientsMAO-A levelsHealthy subjectsPositron emission tomographyTest-retest variabilityMechanism of actionEffective antidepressant treatment strategiesSex-matched healthy subjectsEmission tomographyAntidepressant treatment strategiesMonoamine oxidaseTreatment-resistant depressionTreatment-resistant patientsSerotonin 1A receptorUnmedicated depressed patientsCerebral monoamine oxidasesCerebral MAOAntidepressant pharmacotherapyECT sessionsAntidepressant treatmentDepressed patientsMajor depressionSerotonergic systemTreatment strategies
2017
Effects of Selective Serotonin Reuptake Inhibitors on Interregional Relation of Serotonin Transporter Availability in Major Depression
James GM, Baldinger-Melich P, Philippe C, Kranz GS, Vanicek T, Hahn A, Gryglewski G, Hienert M, Spies M, Traub-Weidinger T, Mitterhauser M, Wadsak W, Hacker M, Kasper S, Lanzenberger R. Effects of Selective Serotonin Reuptake Inhibitors on Interregional Relation of Serotonin Transporter Availability in Major Depression. Frontiers In Human Neuroscience 2017, 11: 48. PMID: 28220069, PMCID: PMC5292566, DOI: 10.3389/fnhum.2017.00048.Peer-Reviewed Original ResearchSelective serotonin reuptake inhibitorsPositron emission tomographySerotonin reuptake inhibitorsMajor depressive disorderHealthy controlsReuptake inhibitorsSerotonergic neurotransmissionBrain regionsState functional magnetic resonance imaging studySerotonin transporterMagnetic resonance imaging studyReuptake of serotoninSerotonin transporter availabilityResonance imaging studyFunctional magnetic resonance imaging studyAnterior cingulate cortexSSRI doseAntidepressant effectsAntidepressant treatmentClinical outcomesSSRI administrationMDD patientsDepressive disorderMajor depressionMDD pathophysiology
2014
Meta-Analysis of Molecular Imaging of Serotonin Transporters in Major Depression
Gryglewski G, Lanzenberger R, Kranz GS, Cumming P. Meta-Analysis of Molecular Imaging of Serotonin Transporters in Major Depression. Cerebrovascular And Brain Metabolism Reviews 2014, 34: 1096-1103. PMID: 24802331, PMCID: PMC4083395, DOI: 10.1038/jcbfm.2014.82.Peer-Reviewed Original ResearchConceptsMajor depressive disorderSerotonin selective reuptake inhibitorsBrains of patientsSeverity of depressionMolecular imaging findingsPositron emission tomographySerotonin reuptake sitesSingle photon emissionMore severe reductionsSignificant comorbiditiesReuptake inhibitorsImaging findingsMDD patientsControl subjectsMonoamine theoryReuptake sitesDepressive disorderSerotonergic neurotransmissionMajor depressionMolecular imaging studiesStudy populationCingulate cortexMeta-AnalysisEmission tomographyImaging studies